Navigation Links
PharmAthene Reports First Quarter 2012 Financial Results
Date:5/8/2012

ive agent of smallpox, and related products, once SIGA receives the first $40 million in net profits from sales of ST-246.  For more information about PharmAthene, please visit www.PharmAthene.com.

Statement on Cautionary Factors Except for the historical information presented herein, matters discussed may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; "should"; "will"; "project"; "potential"; or similar statements are forward-looking statements. PharmAthene disclaims any intent or obligation to update these forward-looking statements other than as required by law. Risks and uncertainties include risk associated with the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates, unexpected funding delays and/or reductions or elimination of U.S. government funding for one or more of the Company's development programs, the award of government contracts to our competitors, unforeseen safety issues, challenges related to the development, scale-up, technology transfer, and/or process validation of manufacturing processes for our product candidates, unexpected determinations that these product candidates prove not to be effective and/or capable of being marketed as products, challenges related to the implementation of our NYSE Amex compliance plan as well as risks detailed from time to time in PharmAthene's Forms 10-K and 10-Q under the caption
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. PharmAthene Presents Update on SparVax™ rPA Anthrax Vaccine Program at the 2012 World Vaccine Congress
2. PharmAthene Secures $7.5 Million Credit Facility From GE Capital, Healthcare Financial Services
3. PharmAthene to Present at the 24th Annual ROTH Conference on Monday, March 12, 2012
4. PharmAthene to Present at the Noble Financial Eighth Annual Equity Conference on Tuesday, January 17, 2012
5. PharmAthene Reports Third Quarter 2011 Financial and Operating Results
6. PharmAthene Progresses Second Generation rPA Anthrax Vaccine
7. PharmAthene Appoints Brian A. Markison to the Companys Board of Directors
8. PharmAthene Achieves Significant Progress in SparVax™ Anthrax Vaccine Program
9. Department of Defense Awards $5.7 Million Contract to PharmAthene for Nerve Agent Medical Countermeasure Program
10. PharmAthene Selected for Inclusion in the Russell Global Index and Russell 3000 Index
11. PharmAthene Achieves Anthrax Vaccine Program Milestone and Successfully Completes Technology Transfer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... ANGELES , May 21, 2015  CytRx ... and development company specializing in oncology, today announced ... clinical trial with aldoxorubicin for the treatment of ... brain cancer.  The open-label, multisite trial is designed ... aldoxorubicin in patients whose tumors have progressed following ...
(Date:5/21/2015)... King of Prussia, PA (PRWEB) May 21, 2015 ... that Julia O’Neill has joined the firm as senior ... more than 30 years of experience in the management ... the vaccines, biologics, pharmaceutical and chemical industries. , “We’re ... enhance our longstanding capabilities in data analytics,” said Dr. ...
(Date:5/20/2015)... , May 20, 2015  Select Medical ... the Federal Trade Commission granted early termination of ... Improvements Act of 1976, as amended, applicable to ... Acquisition Corporation, a joint venture that Select has ... As previously announced, MJ Acquisition Corporation ...
(Date:5/20/2015)... , May 20, 2015  Haemonetics Corporation (NYSE: ... President & CEO, will present at The Jefferies 2015 ... on June 1 st , 2015 at 8:30am ... Mr. Concannon,s presentation live via webcast at: ... (NYSE: HAE ) is a global healthcare company ...
Breaking Biology Technology:CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2Select Medical Corporation's Proposed Acquisition of Concentra Inc. through Joint Venture with Welsh Carson Receives Antitrust Clearance 2
... Diana Davis, PhD, Aiguo Zhang, PhD, Chloe Etienne, Ivan Huang,and Michele Malit, Bio-Rad ... , Introduction ... multiplex sandwich immunoassays. , The concentrations of ... quantitated using a calibration or standard curve. More specifically, , ...
... Maria C Jenmalm, 1 Michele Malit, 2 Jim Torrence, 2 , ... 1 Department of Molecular and Clinical Medicine, Division of Paediatrics, , ... Nobel Drive, Hercules, CA 94547 USA , ... Cytokines play a significant role in hematopoiesis, inflammation, and , ...
... , Matthew W. Fields, Section of Microbiology, Cornell ... Introduction , ... organisms by quantitating mRNA levels. The relative abundance of mRNA ... blots, but these , methods depend on accurate ...
Cached Biology Technology:Principles of Curve Fitting for Multiplex Sandwich Immunoassays, Rev B 2Principles of Curve Fitting for Multiplex Sandwich Immunoassays, Rev B 3Principles of Curve Fitting for Multiplex Sandwich Immunoassays, Rev B 4Principles of Curve Fitting for Multiplex Sandwich Immunoassays, Rev B 5Principles of Curve Fitting for Multiplex Sandwich Immunoassays, Rev B 6Principles of Curve Fitting for Multiplex Sandwich Immunoassays, Rev B 7Principles of Curve Fitting for Multiplex Sandwich Immunoassays, Rev B 8Bio-Plex Cytokine Immunoassays and ELISA: Comparison of Two Methodologies in Testing Samples From Asthmatic and Healthy Children, Rev A 2Bio-Plex Cytokine Immunoassays and ELISA: Comparison of Two Methodologies in Testing Samples From Asthmatic and Healthy Children, Rev A 3Bio-Plex Cytokine Immunoassays and ELISA: Comparison of Two Methodologies in Testing Samples From Asthmatic and Healthy Children, Rev A 4Bio-Plex Cytokine Immunoassays and ELISA: Comparison of Two Methodologies in Testing Samples From Asthmatic and Healthy Children, Rev A 5Quantitation of RNA for Hybridization Blots Using the VersaFluor Fluorometer 2
(Date:4/8/2015)... , April 8, 2015  Infinisource, a leading ... services, and Morpho, a leading supplier of biometric ... produce the market,s most advanced biometrically-enabled time clock, ... NXG time clock is setting a bold, new ... data for the small and mid-size employer. When ...
(Date:4/2/2015)... In the current eight ... the strongest competitors, showing outstanding performance in recognition ... is capable of a throughput of 5.000.000 fingerprints ... be ten times faster than most competitors and ...      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ) , ...
(Date:4/2/2015)... GOTHENBURG, Sweden , April 2, 2015 ... revenues for Q1 2015 attributed to somewhat higher than ... company in the year-end report 2014 that revenues for ... MSEK that the company reported for Q4 2014. The ... continue to be negative. The complete interim report will ...
Breaking Biology News(10 mins):iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Fingerprint Cards Revises Revenues for Q1 2015 2
... Since its inception in 2009, the " Contributions to the ... ZooKeys has been playing an important role in ... North America. With a total of 49 publications by 38 ... publications such as Canadian Staphylinidae. Geographic coverage in ...
... University of Granada researchers have designed a guideline for physicians ... disease that makes the subject develop reverse sex, which occurs ... genes. AIS has low prevalence (it only affects one ... of tissues to respond to the action of male hormones. ...
... GSA Bulletin papers published online 11 Jan. 2013 include ... UK, and New Zealand. Multiple locations in the western U.S. ... Guatemala. Papers cover , 1. Holocene record of ... salt, and the fossil forests of Joggins Fossil Cliffs UNESCO ...
Cached Biology News:ZooKeys opens the gates to America's moth diversity 2Study of a rare disease making people look like a woman but having male genitals under study 2GSA Bulletin starts 2013 with 13 new papers published online ahead of print 2GSA Bulletin starts 2013 with 13 new papers published online ahead of print 3GSA Bulletin starts 2013 with 13 new papers published online ahead of print 4GSA Bulletin starts 2013 with 13 new papers published online ahead of print 5GSA Bulletin starts 2013 with 13 new papers published online ahead of print 6GSA Bulletin starts 2013 with 13 new papers published online ahead of print 7GSA Bulletin starts 2013 with 13 new papers published online ahead of print 8GSA Bulletin starts 2013 with 13 new papers published online ahead of print 9GSA Bulletin starts 2013 with 13 new papers published online ahead of print 10GSA Bulletin starts 2013 with 13 new papers published online ahead of print 11
Request Info...
... Kit Components , 25 g Blocking Reagent , ... 10 ml T7 Elution Buffer , 0.2 ml ... , 0.2 ml BLT5615 glycerol stock , 1010 ... Negative Control Lysate , 50 l S-protein HRP Conjugate ...
Attoglow Western Blot Enhancing Kit contains Millennium Enhancer which can significantly boost Western blot signals, and is compatible with other enhancing mechanisms to achieve multiplied enhancing ...
...
Biology Products: